Cargando…

Comparison of Efficacy and Safety of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis

The present meta-analysis was conducted to compare the safety and efficacy of angiontensin receptor neprilysin inhibitor (ARNI) with angiotensin receptor blockers (ARBs) and angiotensin-converting-enzyme inhibitors (ACEi) in patients with heart failure with reduced ejection fraction (HFrEF). This me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haseeb, Muhammad Talha, Nouman Aslam, Muhammad, Avanteeka, FNU, Khalid, Umar Abdul Rehman, Zubaer Ahmad, Dewan, Senaratne, Mithum, Almaalouli, Bsher, Hirani, Shamsha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Cardiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114261/ https://www.ncbi.nlm.nih.gov/pubmed/37090394 http://dx.doi.org/10.7759/cureus.36392

Ejemplares similares

Role of Ivabradine in Patients with Heart Failure with Preserved Ejection Fraction
por: Nadeem, Muhammad, et al.
Publicado: (2020)

Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials
por: Bratsos, Sosipatros
Publicado: (2019)

Heart Failure Treatments Such As Angiotensin Receptor/Neprilysin Inhibitor Improve Heart Failure Status and Glucose Metabolism
por: Kashiwagi, Yusuke, et al.
Publicado: (2022)

The Dilemma of Use of Anticoagulation in Patients With Heart Failure With Reduced Ejection Fraction and Sinus Rhythm: A Case Report and Literature Review
por: Haseeb ul Rasool, Muhammad, et al.
Publicado: (2023)

Deciphering the Dilemma: Anticoagulation for Heart Failure With Preserved Ejection Fraction (HFpEF)
por: Jyotsna, FNU, et al.
Publicado: (2023)

Heart Failure with Preserved Ejection Fraction: Can Device Therapy Be Our Option?
por: Ahmed, Talha
Publicado: (2020)

Effects of Angiotensin Receptor-Neprilysin Inhibitors Versus Enalapril or Valsartan on Patients With Heart Failure: A Systematic Review and Meta-Analysis
por: Jain, Arpit, et al.
Publicado: (2023)

The Efficacy of Angiotensin Receptor-Neprilysin Inhibitor Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Post Myocardial Infarction: A Meta-Analysis
por: Kotak, Sohny, et al.
Publicado: (2023)

Safety and Efficacy of Istaroxime in Patients With Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials
por: Khalid Khan, Saad, et al.
Publicado: (2023)

Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction
por: Park, Su Yeong, et al.
Publicado: (2023)

Improvement in quality of life with sacubitril/valsartan in cardiac resynchronization non-responders: The RESINA (RESynchronization plus an Inhibitor of Neprilysin/Angiotensin) registry
por: Campal, José Manuel Rubio, et al.
Publicado: (2021)

Comparison of Effectiveness and Safety of Low-Dose Versus Standard-Dose Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke: A Meta-Analysis
por: Karedath, Jithin, et al.
Publicado: (2023)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
por: Malik, Jahanzeb, et al.
Publicado: (2021)

Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction
por: Grant, Andrew D.M., et al.
Publicado: (2020)

Inspiratory Muscle Training in Patients With Heart Failure With Preserved Ejection Fraction: A Meta-Analysis
por: Baral, Nischit, et al.
Publicado: (2020)

Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40%
por: Zhao, Mingyue, et al.
Publicado: (2019)

Impact of angiotensin receptor–neprilysin inhibition on vascular function in heart failure with reduced ejection fraction: A pilot study
por: Nathaniel, Sangeetha, et al.
Publicado: (2022)

Impact of Primary Percutaneous Coronary Intervention on Complete Atrioventricular Block With Acute Inferior ST-Elevation Myocardial Infarction
por: Malik, Jahanzeb, et al.
Publicado: (2020)

Assessment of health-related quality of life in hypertensive hemodialysis patients
por: Aslam, Ayesha, et al.
Publicado: (2022)

American Heart Association High Blood Pressure Protocol 2017: A Literature Review
por: Ali, Asad, et al.
Publicado: (2018)

Long-Term Effects of Angiotensin Receptor–Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction
por: Poglajen, Gregor, et al.
Publicado: (2020)

Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40%: Retraction
Publicado: (2019)

Physician adherence and patient-reported outcomes in heart failure with reduced ejection fraction in the era of angiotensin receptor-neprilysin inhibitor therapy
por: Kim, In-Cheol, et al.
Publicado: (2022)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Unexpected Reduced Biventricular Ejection Fraction in a Healthy Young Male
por: Sanchez-Nadales, Alejandro, et al.
Publicado: (2020)

Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF)
por: Parikh, Riya R, et al.
Publicado: (2022)

Comparison Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Incidence of Lung Cancer: A Retrospective Study
por: Kumar, Pardeep, et al.
Publicado: (2021)

Immunomodulatory Therapy for Giant Cell Myocarditis: A Narrative Review
por: Naseeb, Muhammad Wahdan, et al.
Publicado: (2023)

Management of Heart Failure With Preserved Ejection Fraction in Elderly Patients: Effectiveness and Safety
por: Elkammash, Amr, et al.
Publicado: (2023)

Energy Drinks and Atrial Fibrillation: An Unusual Case of Caution
por: Hanif, Muhammad, et al.
Publicado: (2020)

Association Between Myocardial Scar Burden and Left Ventricular Ejection Fraction in Ischemic Cardiomyopathy
por: Aboul Enein, Fatma, et al.
Publicado: (2020)

Role of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction: A Review Article
por: Mgbemena, Okechukwu, et al.
Publicado: (2021)

Multivessel Spontaneous Coronary Artery Dissection: Amberen as a Possible Risk Factor
por: Nesheiwat, Zeid, et al.
Publicado: (2019)

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
por: Ryazanov, A.S., et al.
Publicado: (2023)

Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats
por: Miyoshi, Toru, et al.
Publicado: (2019)

Physician Variability in Diastology Reporting in Patients With Preserved Ejection Fraction: A Single Center Experience
por: Patel, Raj, et al.
Publicado: (2020)

The Effect of Sacubitril-Valsartan on Ventricular Arrhythmia Burden in Patients With Heart Failure With Reduced Ejection Fraction
por: Medeiros, Paulo, et al.
Publicado: (2023)

The Importance of Serum N-Terminal Pro-Brain Natriuretic Peptide and Endogenous Hydrogen Sulfide for Predicting Coronary Artery Lesions in Pediatric Kawasaki Disease Patients: Findings From a Tertiary Care Hospital in Karachi, Pakistan
por: Bilal, Muhammad, et al.
Publicado: (2020)

Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP‐HF
por: Chapman, Brittany, et al.
Publicado: (2022)

Long-term effects of angiotensin receptor neprilysin inhibitor therapy in heart failure patients with reduced ejection fraction: A retrospective cohort study
por: Koçak, Ajar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i2a8l3c63viqil2995n4vrqnp9